logo
ProjectEnded

RAPID MIGRAINE RELIEF WITH ALGINATE-BASED THIN FILM

The status, timeline and source of this project. A free account opens every field.

Source: EU Funding & Tenders Portal

Klaria's business concept is based on developing and commercializing innovative, fast-acting medicinal products with clear competitive benefits in the therapeutic fields of migraine and cancer-related pain. Migraine is the sixth most disabling illness in the world. The economic burden of migraine predominantly falls on patients and their employers in the form of bedridden days and lost productivit

Status
Closed
Sector
Manufacturing (Industrial)
Location
Sweden
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about RAPID MIGRAINE RELIEF WITH ALGINATE-BASED THIN FILM

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “RAPID MIGRAINE RELIEF WITH ALGINATE-BASED THIN FILM” is an infrastructure initiative in the Manufacturing (Industrial) sector, located in Sweden. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Klaria's business concept is based on developing and commercializing innovative, fast-acting medicinal products with clear competitive benefits in the therapeutic fields of migraine and cancer-related pain. Migraine is the sixth most disabling illness in the world. The economic burden of migraine predominantly falls on patients and their employers in the form of bedridden days and lost productivity. The illness is three times as common in women than in men. However, existing drug delivery methods are not effective which results in low therapy satisfaction rates amongst migraine patients. Klaria developed an alginate-based polymer film capable of rapidly delivering the API (active pharmaceutical ingredient) directly into the bloodstream. The thin film is similar to a small postage stamp and is discreetly attached to the oral mucous membrane and allows the medication to be distributed into the bloodstream through the oral mucous membrane. The substance is delivered much more quickly (and thereby has a faster impact) than substances which are swallowed in tablets or capsules. Klaria’s film does not require taking an injection or suppository and ensures early intervention which is critical in order for migraine patients to experience pain relief. The film can be used by all migraine patients using medications based on triptans including those who experience concomitant vomiting during their migraine attack. Project RAPID, aims therefore to exploit the positive clinical performance of the buccal adhesive film, the company’s IP position and its ability to manufacture cost-effectively to launch an innovative migraine to contribute to an improved quality of life for migraine patients.

Location

Country

Sweden

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Manufacturing (Industrial)

Article published date

2026-02-01

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project